Fidaxomicin vs Vancomycin for Clostridioides difficile Infection
Author Information
Author(s): Pettit Natasha N. PharmD, Lew Alison K. PharmD, Nguyen Cynthia T. PharmD, Bell Elizabeth MD, Lehmann Christopher J. MD, Pisano Jennifer MD
Primary Institution: University of Chicago Medicine
Hypothesis
Does fidaxomicin reduce rates of recurrent Clostridioides difficile infection compared to vancomycin in high-risk patients?
Conclusion
Fidaxomicin did not show a significant advantage over vancomycin in preventing recurrent Clostridioides difficile infections among high-risk patients.
Supporting Evidence
- Rates of recurrent CDI were similar between patients treated with fidaxomicin and those treated with vancomycin.
- Subgroup analyses did not identify any specific risk factors that improved outcomes with fidaxomicin.
- Patients receiving fidaxomicin had a higher rate of ESBL colonization compared to those receiving vancomycin.
Takeaway
This study looked at two medicines for a gut infection and found that one didn't work better than the other for people who are more likely to get sick again.
Methodology
This was a pre-post quasi-experimental study comparing outcomes of patients treated with fidaxomicin or vancomycin for Clostridioides difficile infection.
Potential Biases
Potential confounding factors included reliance on patient charts for data accuracy and the retrospective nature of the study.
Limitations
The study relied on presumptive diagnoses of CDI and may not be applicable to other hospitals with different diagnostic approaches.
Participant Demographics
Participants included adults aged 65 and older, immunocompromised individuals, and those with severe CDI.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website